PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Neuropharmacology. Author manuscript; available in PMC Sep 1, 2009.
Published in final edited form as:
PMCID: PMC2613007
NIHMSID: NIHMS68981
CUE-INDUCED REINSTATEMENT OF ALCOHOL-SEEKING BEHAVIOR IS ASSOCIATED WITH INCREASED ERK1/2 PHOSPHORYLATION IN SPECIFIC LIMBIC BRAIN REGIONS: BLOCKADE BY THE MGLUR5 ANTAGONIST MPEP
Jason P. Schroeder,a Marina Spanos, Jennie R. Stevenson, Joyce Besheer, Michael Salling, and Clyde W. Hodgeb
Department of Psychiatry, Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill, Thurston-Bowles Building; CB #7178, Chapel Hill, NC 27599
aPresent address: Department of Human Genetics, Emory University, Whitehead 301, 615 Michael St., Atlanta, GA 30322
bCorrespondence: Clyde W. Hodge, Ph.D., Department of Psychiatry, University of North Carolina at Chapel Hill, Thurston Bowles Building; CB #7178, Chapel Hill, NC 27599, Voice: 919-843-4823, Fax: 919-966-5679, Email: chodge/at/med.unc.edu
Relapse to alcohol use after periods of abstinence is a hallmark behavioral pathology of alcoholism and a major clinical problem. Emerging evidence indicates that metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate relapse to alcohol-seeking behavior but the molecular mechanisms of this potential therapeutic effect remain unexplored. The extracellular signal-regulated kinase (ERK1/2) pathway is downstream of mGluR5 and has been implicated in addiction. We sought to determine if cue-induced reinstatement of alcohol-seeking behavior, and its reduction by an mGluR5 antagonist, is associated with changes in ERK1/2 activation in reward-related limbic brain regions. Selectively bred alcohol-preferring (P) rats were trained to lever press on a concurrent schedule of alcohol (15% v/v) vs. water reinforcement. Following 9 days of extinction, rats were given an additional extinction trial or injected with the mGluR5 antagonist MPEP (0, 1, 3, or 10 mg/kg) and tested for cue-induced reinstatement. Brains were removed 90-min later from the rats in the extinction and MPEP (0 or 10 mg/kg) conditions for analysis of p-ERK1/2, total ERK1/2, and p-ERK5 immunoreactivity (IR). Cue-induced reinstatement of alcohol-seeking behavior was associated with a 3–5 fold increase in p-ERK1/2 IR in the basolateral amygdala and nucleus accumbens shell. MPEP administration blocked both the relapse-like behavior and increase in p-ERK1/2 IR. P-ERK1/2 IR in the central amygdala and NAcb core was dissociated with the relapse-like behavior and the pharmacological effect of mGluR5 blockade. No changes in total ERK or p-ERK5 were observed. These results suggest that exposure to cues previously associated with alcohol self-administration is sufficient to produce concomitant increases in relapse-like behavior and ERK1/2 activation in specific limbic brain regions. Pharmacological compounds, such as mGluR5 antagonists, that reduce cue-induced ERK1/2 activation may be useful for treatment of relapse in alcoholics that is triggered by exposure to environmental events.
Keywords: Alcoholism, Alcohol Reinforcement, Relapse, Cue-Induced Reinstatement, ERK/MAPK, ERK1/2, mGluR5, MPEP, Alcohol preferring P-rats
Alcoholism is a complex neuropsychiatric disorder that is characterized by recurring cycles of chronic drinking, abstinence and relapse. Emerging evidence suggests that alcohol and other drugs of abuse may produce maladaptive changes in a variety of molecular and cell signaling pathways that lead to enduring changes in brain structure and function (Crews et al., 1996; Fadda and Rossetti, 1998; Nestler and Aghajanian, 1997). These neuroadaptations are thought to regulate the progressive and recurring behavioral pathologies that occur in alcoholism (Breese et al., 2005; Pandey et al., 2003; Ron and Jurd, 2005). Understanding drug-induced plasticity in brain and behavioral functions is of potential importance for development of new pharmacotherapies for problems associated with alcoholism, such as relapse (Anton et al., 1995; Heinz et al., 2003; Mann, 2004).
A growing number of studies have shown that metabotropic glutamate receptor 5 (mGluR5) activity regulates alcohol-related behavioral processes in animal models. For example, the mGluR5 antagonist 2-Methyl-6-(phenylethynyl)pyridine hydrochloride (MPEP) inhibits the reinforcing (Cowen et al., 2005; Hodge et al., 2006; Schroeder et al., 2005) and discriminative stimulus effects of investigator- (Besheer and Hodge, 2005) and self-administered (Besheer et al., 2006) alcohol in rodents. Similarly, pharmacological blockade of mGluR5 prevents relapse-like behavior as measured by cue-induced reinstatement (Backstrom et al., 2004) and alcohol deprivation procedures (Schroeder et al., 2005). Although these findings indicate mGluR5 blockade attenuates relapse to alcohol-seeking behavior, the molecular or cell signaling mechanisms associated with this potential therapeutic effect remain unexplored.
Extracellular signal-regulated kinase (ERK) is one potential downstream mediator of mGluR5 activity (Yang et al., 2004) that is also known to modulate adaptive processes such as learning, memory, and synaptic plasticity (Sweatt, 2004; Thomas and Huganir, 2004) as well as maladaptive forms of plasticity associated with drug use (Girault et al., 2007; Valjent et al., 2006). The two closely related isoforms of ERK (ERK1 and ERK2, or ERK1/2) are activated by dual phosphorylation on both a threonine and tyrosine residue by MEK1/2 (Anderson et al., 1990); reviewed by (Cobb, 1999). Activated ERK1/2 phosphorylates cellular targets or translocates to the nucleus where it activates specific gene transcription factors (Grewal et al., 1999). By regulating cellular activities and gene transcription, the ERK1/2 cascade transduces the activity of a variety of extracellular and intracellular signals into enduring changes in CNS structure and function (Pearson et al., 2001; Qi and Elion, 2005; Treisman, 1996; Valjent et al., 2000; Valjent et al., 2006).
Alcohol exposure produces changes in the active (i.e., phosphorylated) form of ERK1/2 (p-ERK1/2) in brain regions that are of significance to behavioral pathologies associated with addiction (Chandler and Sutton, 2005; Davis et al., 1999; Kalluri and Ticku, 2002a; Sanna et al., 2002; Tsuji et al., 2003). For example, acute ethanol has been shown to produce a dose- and time-dependent decrease in p-ERK1/2 levels in mouse and rat cerebral cortex (Chandler and Sutton, 2005; Kalluri and Ticku, 2002b; Tsuji et al., 2003); but other studies have shown that acute ethanol increases ERK1/2 phosphorylation in the Edinger-Westphal nucleus (Bachtell et al., 2002) and amygdala (Pandey et al., 2008). Forced exposure to chronic ethanol and withdrawal alter ERK1/2 phosphorylation in brain regions that regulate alcohol self-administration and relapse-like behavior, including the amygdala (Pandey et al., 2008; Sanna et al., 2002).
Although the mechanisms by which alcohol alters ERK1/2 phosphorylation are not fully characterized, converging evidence indicates that mGluR5 may regulate both ERK1/2 activation and the neural effects of alcohol. For example, pharmacological activation of Group I metabotropic glutamate receptors (mGluR1 and mGluR5), via site-specific infusion of the agonist DHPG, increases ERK1/2 phosphorylation in rat striatum (Choe and Wang, 2001). This effect of the nonselective agonist is fully blocked by the mGluR5 antagonist MPEP in cultured striatal neurons but not altered by an mGluR1 antagonist (Yang et al., 2004), which suggests mGluR5 specificity in ERK1/2 activation. Other data show that ethanol inhibits mGluR5 activity in vitro (Minami et al., 1998), which could lead to reduced ERK1/2 activation as noted above. When taken together with evidence that cue-induced reinstatement of alcohol-seeking behavior has recently been linked to increase ERK1/2 phosphorylation in the amygdala (Radwanska et al., 2008), these findings suggest that mGluR5 antagonist-induced effects on relapse-like behavior may be associated inhibition of ERK1/2 activation in specific brain regions.
To address this hypothesis, the present study was designed to first determine if the mGluR5 antagonist MPEP would inhibit cue-induced reinstatement of alcohol-seeking behavior in selectively-bred alcohol-preferring (P) rats (Li et al., 1979). Second, we examined p-ERK1/2 immunoreactivity (IR) in the nucleus accumbens and amygdala following extinction, reinstatement, and MPEP treatment to determine if the behavioral effects of MPEP are associated with altered ERK 1/2 activation. These brain regions were chosen for study because they are key elements in the neurobiological regulation of associative learning processes in drug addiction and reward (Everitt et al., 1999), are known to mediate the reinforcing and subjective effects of alcohol (Besheer et al., 2003; Hodge et al., 1995; Hodge and Cox, 1998; Schroeder et al., 2003), and have recently been linked to alcohol relapse-like behavior in rodents (Dayas et al., 2007; Zhao et al., 2006) and cue-induced craving in abstinent human alcoholics (Schneider et al., 2001). Third, we examined total ERK1/2 IR to establish if changes in p-ERK1/2 IR were associated with altered abundance of the kinase. Finally, adjacent brain sections were processed for p-ERK5 IR in an effort to address potential specificity of ERK1/2 activation in cue-induced reinstatement of alcohol-seeking behavior and its blockade by MPEP.
Animals
Male alcohol-preferring (P) rats (N=31 total) were bred from a line provided by Indiana University (courtesy of Dr. T.K. Li) and housed two per cage in Plexiglas cages. This rat strain was chosen for study because it has been found to fulfill the requirements of an animal model of alcoholism (Cicero, 1979; Lester and Freed, 1973), including voluntarily consumption of alcohol in quantities that produce significant blood alcohol concentrations (50–200 mg%), self-administration of alcohol for its pharmacological rather than the sensory effects and development of tolerance and dependence through voluntary drinking (Kampov-Polevoy et al., 2000; Li et al., 1987; Murphy et al., 2002). The animal colony room was maintained on a 12L: 12D cycle with the lights on at 07:00. All experimental procedures were conducted under institutional and NIH guidelines.
Self-Administration Apparatus
Self-administration, extinction, and reinstatement sessions were conducted in Plexiglas operant chambers for rats (Med Associates, Georgia, VT). Each chamber was housed in a sound-attenuating cubicle equipped with a fan that provided ventilation and helped to mask external noise. The left and right wall of each operant chamber was equipped with one ultra-sensitive stainless steel response lever, a cue-light, and a liquid delivery system. Liquid solutions (ethanol or water) were maintained in 60 ml syringes mounted on a programmable pump (PHM-100, Med Associates), which delivered 0.1 ml per activation into a stainless steel cup located to the left of the associated response lever. Head entries into the drinking cup were recorded when an infrared photo beam was broken. Each chamber also contained a house light. The chambers were interfaced (Med Associates) to an IBM-PC compatible computer.
Self-Administration, Extinction, and Reinstatement Procedure
After 2 weeks of adaptation to laboratory housing conditions, fluid access was restricted to 1-h per day (for 2 days only) and the rats were trained to lever press by reinforcement of successive approximations with sucrose (10% w/v) vs. water available as reinforcers on a concurrent fixed ratio-1 (CONC FR1-FR1) schedule of reinforcement during two 16-h overnight sessions. Daily (M-F) 30-min sessions were conducted with sucrose (10% w/v) vs. water available concurrently. When sucrose and water responding stabilized (i.e., <10% daily variation for 5 days), the rats were trained to self-administer concurrent ethanol (15% v/v) vs. water using a sucrose fading procedure (Samson, 1986) as previously described (Hodge et al., 1993). Briefly, ethanol was added to the sucrose solution over a 4-week period and then the sucrose was faded out of the solution until P-rats were self-administering 15% ethanol vs. water. During operant training sessions, responses on the ethanol-paired lever resulted in the presentation of a compound stimulus consisting of a visual cue light and the auditory stimulus of pump activation from a fixed spatial location. Responses on the water-paired lever resulted in the presentation of a similar compound stimulus, but from an alternate fixed spatial location.
Following a 1-month period of baseline responding, operant responding was extinguished by removing all consequences of lever responding (i.e., cue-light, pump sound, and ethanol or water delivery). Following 9 sequential days of extinction training, P-rats responded upon the formerly alcohol and water paired levers equivalently, indicating an extinction of selective responding on the alcohol-paired lever. On day 10, the P-rats were given a reinstatement test in which lever press responses were followed by presentation of the cue light and auditory cue (as during training) in the absence of ethanol or water reinforcement to examine cue-induced ethanol-seeking behavior. One hour prior to the reinstatement session 4 separate groups of P-rats were injected with the mGluR5 antagonist MPEP (0, 1, 3 or 10 mg/kg) to determine if MPEP alters cue-induced reinstatement of alcohol-seeking behavior in this genetic model of alcoholism. Each drug dose group consisted of n=6 rats with the exception of the MPEP (1 mg/kg) group, which was n=7 rats. A fifth group of P-rats (n=6) was given another day of extinction training to serve as a control for the reinstatement conditions. Groups were matched on body weight, baseline response totals, and extinction performance prior to drug testing.
Drugs
Ethanol solutions were prepared by mixing appropriate volumes of ethanol (95% v/v) and distilled water. Sucrose (w/v) solutions consisted of granulated cane sugar dissolved in distilled water. Ethanol, sucrose, and water solutions were presented at room temperature. MPEP (Tocris Bioscience, Ellisville, Missouri) was dissolved in physiological saline and injected in a volume of 1 ml/kg body weight.
Immunohistochemistry
Ninety minutes after the reinstatement test session, rats were deeply anesthetized with pentobarbital (100 mg/kg IP) and transcardially perfused with ice cold 0.1 M phosphate buffered saline (PBS; pH 7.4) followed by 4% paraformaldehyde. The intact skulls were postfixed overnight, and then rinsed with PBS. Brains were removed from the skull and stored in PBS at 4°C. Coronal vibratome sections (40 µm) were collected and stored (−20°C) in cryoprotectant until immunohistochemistry processing. Endogenous peroxidase was blocked by incubating the free floating sections for 10 min in 0.6% H2O2 followed by citra buffer antigen retrieval performed at 70°C for 30 min (Antigen Retrieval Citra, BioGenex, San Ramon, CA). Sections were blocked in PBS/0.1%triton-x/4% horse serum for 30 minutes and incubated at +4°C overnight in primary polyclonal antibody to p-ERK1/2 (1:400), ERK1/2 (1:500), or p-ERK5 (1:1000) from Cell Signaling Technology (Danvers, MA). The sections were then incubated in secondary antibody for one hour using the Dako EnVision Kit (Dako, Carpinteria, CA). Immunoreactivity was detected with nickel-enhanced diaminobenzidine (Dako EnVision Kit) as a chromagen. Sections were then counterstained with toluidine blue, mounted, dried and coverslipped with Cytoseal. For consistency of staining across subjects, brain tissue from all groups was processed simultaneously.
Immunoreactivity was visualized using an Olympus CX41 light microscope (Olympus America, Center Valley, PA). Images were acquired using a digital camera (Regita model, QImaging, Burnaby, BC) interfaced to a desktop computer (Dell, Round Rock, TX). Image analysis software (Bioquant Nova Advanced Image Analysis; R&M Biometric, Nashville, TN) was used to quantify immunoreactivity. The microscope, camera, and software were background corrected and normalized to preset light levels to ensure fidelity of data acquisition. Pixel density and cell count measurements were calculated from a circumscribed field (e.g., brain region) and divided by the area of the region and expressed as pixels/mm2. Immunoreactivity data were collected by a researcher blind to treatment conditions. Data for p-ERK1/2 IR data were acquired from a minimum of 4 sections/brain region/animal and averaged to obtain a single value per subject. Total ERK1/2 and p-ERK5 IR were evaluated in a single section adjacent to those used for p-ERK1/2 from each animal. The brain regions examined were the nucleus accumbens (core and shell; AP +1.7 to 1.0 mm; see Figure 2B) and the amygdala (basolateral and central nucleus; AP −2.8 to 3.3 mm; see Figure 2C).
Figure 2
Figure 2
p-ERK1/2 IR in nucleus accumbens shell
Data Analysis
The principal behavioral parameters of operant ethanol self-administration analyzed were number of ethanol and water lever presses, volume of ethanol consumed (mls), and response latency (i.e., temporal delay to the first ethanol response). Ethanol intake (g/kg) was determined using each animal’s daily body weight and the volume of ethanol delivered per reinforcer (0.1 ml of 15% v/v ethanol). Extinction data were analyzed statistically by two-way repeated measures analysis of variance (RM ANOVA) with factors for lever (ethanol vs. water) and day. MPEP dose effects on reinstatement were analyzed by two-way RM ANOVA with factors for drug dose (between subjects) and response lever (within subject). Immunohistochemistry data were analyzed statistically by one-way ANOVA. Significant main effects and interactions were followed by post hoc multiple comparisons (Tukey test) test using SigmaStat v. 3.0 (Systat Software, La Jolla, CA)
Baseline Performance
On the last day of baseline P-rats from all treatment groups combined (N=31 total) responded significantly more on the ethanol lever as compared to the concurrently available water lever (F(1,30)=66.8, p<0.0001) (Figure 1A, left). This resulted in an average ethanol dose of 0.81 ± 0.06 g/kg/30-min with a strong preference for ethanol over water of 87.5%, which is typical for this genetically selected rat line (Besheer et al., 2008; Schroeder et al., 2005). A two-way ANOVA (Reinforcer X Treatment Condition) conducted on data from the last day of baseline showed that there were no differences in total ethanol and water reinforced responding among the groups of rats that went on to receive extinction only or extinction followed by MPEP (0, 1, 3, or 10 mg/kg, IP) administration prior to cue-induced reinstatement (F (4, 52)=0.32, p = 0.86, ns). Thus, any subsequent differences seen on reinstatement tests were not likely related to differential baseline performance.
Figure 1
Figure 1
(A) Extinction of alcohol-reinforced lever pressing. Data are plotted as mean (± SEM) total responses per session on the ethanol and water levers on the last day of baseline (left) and through the 9 days of extinction training (right). Data represent (more ...)
Extinction of Alcohol Self-Administration
During the nine days of extinction, rats from all treatment groups (N=31 total) emitted significantly more responses on the lever that previously produced ethanol reinforcement (F(1,30) = 155, p < 0.001) (Figure 1A, right). Although responding on both ethanol and water levers decreased as a function of time (F(8,240) = 58, p <0.001), the magnitude of change was greater for responses on the ethanol lever as indicated by the significant statistical interaction between reinforcement condition (ethanol × water) and time (F(8,240) = 44.5, p < 0.001). Multiple comparison procedures (Tukey test) showed that responses on the ethanol-associated lever decreased as a function of time and were not different from water responding on the last two days (8 and 9) of extinction (Figure 1B, right). Additional analysis of extinction performance using separate two-way ANOVAs showed that there were no differences in total ethanol (F(4,208) = 0.32, ns) or water (F(4,208) = 0.67, p = 0.62, ns) lever responses during the nine days of extinction between the five treatment groups that went on to receive EXTINCTION or EXTINCTION followed by MPEP (0, 1, 3, or 10 mg/kg). These data show extinction of ethanol reinforced responding (i.e., equivalent responding on levers that previously produced ethanol and water reinforcement) in alcohol preferring P-rats when all consequences of lever pressing were removed for 9 days. In addition, subsequent group differences on reinstatement tests were not a function of differential between-group rates of extinction.
Cue-induced Reinstatement of Alcohol-Seeking Behavior: Blockade by MPEP
On day 10 of the procedure, one group of rats was administered a saline pretreatment injection and continued under the extinction condition. The other four groups of rats were pretreated with MPEP (0, 1, 3, or 10 mg/kg) and underwent reinstatement tests in which responses on either the ethanol- or water-associated lever resulted in presentation of discrete cues (stimulus light above the lever and pump sound) that were previously paired with reinforcer delivery during baseline. Overall, the behavioral data demonstrate cue-induced reinstatement of alcohol-seeking behavior that was blocked by the mGluR5 antagonist MPEP (Figure 1B).
Statistical analysis using a two-way repeated measures ANOVA with one factor repetition revealed a significant main effect of reinforcement condition (F (1, 4) = 34.7), p < 0.001) due to an overall increase in responding on the ethanol-associated lever across the 5 treatment conditions (Figure 1B). There was also a significant main effect of treatment condition (F (4, 26) = 4.9, p = 0.004) and interaction between treatment and reinforcement conditions (F (4, 26) = 4.4, p = 0.007), which indicates that the increases in responding on the ethanol lever were dependent on the treatment condition (i.e., Extinction or MPEP dose). Multiple comparison procedures (Tukey test) comparing extinction performance to MPEP (0 mg/kg) showed significant cue-induced reinstatement of ethanol-seeking behavior with no change in responding on the concurrently available water lever (Figure 1B). Moreover, MPEP (1 and 10 mg/kg) selectively blocked cue-induced reinstatement of ethanol-seeking behavior with no significant suppression of water responding (Figure 1B). However, the effect of the middle dose of MPEP (3 mg/kg) did not reach statistical significance due to variability in performance of one rat that responded on the ethanol-associated lever at a rate that was 3 standard errors above the group mean. Otherwise, the response totals following MPEP (3 mg/kg) were indistinguishable from those following the low dose.
ERK1/2 Activation
Nucleus Accumbens (shell and core)
Cue-induced reinstatement of alcohol-seeking behavior and its blockade by MPEP (10 mg/kg) was associated with an overall significant change in p-ERK1/2 IR in the shell of the nucleus accumbens (F (2, 15) = 45.5, p < 0.0001). Multiple comparison procedures showed that cue-induced reinstatement of alcohol-seeking was associated with a 5-fold increase in p-ERK1/2 IR as compared to the extinction condition (Tukey, p<0.05; Figure 2A). Administration of a dose of the mGluR5 antagonist MPEP (10 mg/kg) that blocked cue-induced reinstatement of alcohol-seeking behavior also completely blocked the increase in p-ERK1/2 IR that occurred following saline administration (Tukey, p<0.05; Figure 2A). Additional analysis showed that the increase in p-ERK1/2 IR in the nucleus accumbens shell was the result of a concomitant 5-fold increase (F (2, 15) =61, p < 0.0001) in the number of p-ERK1/2 positive cells / mm2: mean±SEM cells: Ext – (53.25 ±11.48); saline – (281.5±29.86); MPEP 10 mg/kg – (10.40±4.776) indicating a cellular pattern of ERK1/2 activation. No significant (F (2, 15) = 0.84, p = 0.4, ns) changes were observed in total ERK1/2 IR (Table 1) or p-ERK5 IR (Table 2), suggesting that the observed changes were specific to ERK1/2 phosphorylation and not related to altered abundance of the kinase or general activation of mitogen activated protein kinase (MAPK) pathways. Representative photomicrographs illustrating the cytological pattern of p-ERK1/2 IR in the nucleus accumbens shell following extinction and MPEP (0 or 10 mg/kg) are shown in Figure 2C.
Table 1
Table 1
Measures of total ERK1/2 immunoreactivity in the N. Accumbens and Amygdala.
Table 2
Table 2
Measures of p-ERK5 immunoreactivity in the N. Accumbens and Amygdala.
In the nucleus accumbens core, there was an overall trend toward a significant change in p-ERK1/2 IR associated with cue-induced reinstatement but it failed to reach statistical significance (F (2, 16) = 3.5, p = 0.054). Pixel density values (mean±SEM: extinction – 1310±117.7; saline – 1801±207.8; MPEP 10 mg/kg – 1224±151.8) suggested that p-ERK1/2 IR following the saline-reinstatement condition may have been greater than following extinction but a planned comparison (t-test) between these two conditions also failed to reach statistical significance (t (11) = 1.9, p = 0.07), which further confirms the lack of significant change in p-ERK1/2 IR in the nucleus accumbens core. There was also no change in total-ERK1/2 IR (Table 1) or p-ERK5 IR (Table 2) in the nucleus accumbens core.
Amygdala (basolateral and central)
In the basolateral amygdala, cue-induced reinstatement of alcohol-seeking behavior was associated with a significant change in p-ERK1/2 IR (F (2, 15)=26.4, p < 0.0001). Multiple comparison procedures indicated that the overall significant difference was due to a 3-fold increase in p-ERK1/2 IR following the saline-reinstatement condition as compared to extinction (Tukey, p<0.05; Figure 3A). Administration of MPEP (10 mg/kg) prior to the reinstatement test session completely blocked the increase in p-ERK1/2 IR that followed saline administration (Tukey, p<0.05; Figure 3A). Cell count analysis showed that the increase in p-ERK1/2 IR in the basolateral amygdala was associated with a 59% increase (F (2, 15) = 7.2, p = 0.006) in the number of p-ERK1/2 positive cells / mm2: mean±SEM cells: Ext – (153±42); saline – (244±36); MPEP 10 mg/kg – (49±18.7) that the increase in immunoreactivity was partially influenced by an increase in the number of p-ERK1/2 positive cells. No changes were observed in total-ERK1/2 (Table 1) or p-ERK5 IR (Table 2) indicating that observed changes in ERK1/2 phosphorylation were not related to an overall change in kinase abundance or nonspecific activation of MAPK pathways. Figure 3C shows representative photomicrographs of the basolateral amygdala illustrate the cytological pattern of p-ERK1/2 IR under extinction and reinstatement conditions.
Figure 3
Figure 3
p-ERK1/2 IR in basolateral amygdala
By contrast, cue-induced reinstatement of alcohol-seeking behavior was not associated with changes in p-ERK1/2 IR in the central amygdala (i.e., saline-reinstatement not different from extinction). However, one-way ANOVA identified an overall significant F (2,15) = 3.9, p = 0.04) change in p-ERK1/2 IR, which was due primarily to a significant reduction following MPEP (10 mg/kg) during reinstatement as compared to extinction (Tukey, p < 0.05; mean±SEM pixel density values: extinction – 3343±570; saline – 2522±513 ; MPEP 10 mg/kg – 1555±118). This MPEP-induced inhibition of p-ERK1/2 IR was associated with a trend toward a reduction in p-ERK1/2 positive cells (data not shown). No changes were observed in total ERK1/2 IR in the central amygdala (Table 1) indicating that the effects of MPEP (10 mg/kg) were associated with a specific change in ERK1/2 phosphorylation and not abundance of the kinase. There was also no change in p-ERK5 IR in the central amygdala (Table 2).
The results of this study show that the mGluR5 antagonist MPEP blocks relapse-like behavior and an associated upregulation of ERK1/2 activation. Using a rat genetic model of alcoholism, we found that reinstatement of alcohol-seeking behavior, produced by response contingent presentation of alcohol-associated cues, is associated with a profound 3 – 5 fold increase in ERK1/2 phosphorylation specifically in the nucleus accumbens shell and basolateral nucleus of the amygdala. This upregulation of ERK1/2 phosphorylation was solely attributable to cue exposure and the subsequent alcohol-seeking behavior since no alcohol was presented on the test day. Both the increase in ERK1/2 phosphorylation and relapse-like behavior was completely blocked by the mGluR5 antagonist MPEP. We found no changes in total ERK1/2 or in ERK5 phosphorylation, suggesting some degree of specificity for ERK1/2 activation in cue-induced reinstatement. These findings indicate that cue-induced relapse to alcohol-seeking behavior is associated with an upregulation of ERK1/2 phosphorylation (i.e., activation) specifically in sub-nuclei of the amygdala-ventral striatal pathway.
Several recent studies have shown that alcohol exposure alters ERK1/2 phosphorylation. Moderate doses of acute alcohol (1.5 – 3.5 g/kg) produce a dose- and time-dependent decrease in p-ERK1/2 in mouse cortex (Kalluri and Ticku, 2002a). Similarly, another recent study extended these findings by showing that acute ethanol (3.5 g/kg) reduced p-ERK1/2 in the cerebral cortex and hippocampus in rat pups ranging from PND 5 to adulthood (Chandler and Sutton, 2005). Evidence also indicates that the ERK/MAPK system may regulate adaptive changes associated with chronic ethanol exposure and abstinence (Pandey et al., 2008). Forced exposure to chronic ethanol vapor (blood alcohol levels of approximately 200 mg%) suppressed p-ERK1/2 immunoreactivity in the amygdala, cortex, cerebellum, and dorsal striatum in rats (Sanna et al., 2002). Conversely, the same study showed that withdrawal from ethanol vapor resulted in a time-dependent increase in p-ERK1/2 levels that peaked at 13-h post withdrawal and remained elevated at 24-h (Sanna et al., 2002). Our results show that response-contingent exposure to stimuli (i.e., cues) that were previously paired with moderate levels of self-administered alcohol is sufficient to induce a 5-fold increase in ERK1/2 phosphorylation specifically in the nucleus accumbens shell and a 3-fold increase in the basolateral amygdala in alcohol preferring P-rats, and a 3-fold increase in alcohol-seeking behavior. These data in alcohol preferring P-rats confirm and extend prior results showing that non-contingent exposure to alcohol paired stimuli increases p-ERK1/2 IR in the lateral amygdala of Wistar rats (Radwanska et al., 2008). Together, these studies demonstrate that alcohol exposure, withdrawal, and cue-induced reinstatement are associated with adaptive changes in ERK1/2 activation in the mammalian brain.
In the present study, we also found that systemic administration of the mGluR5 antagonist MPEP completely blocked cue-induced increases in both ERK1/2 phosphorylation and alcohol-seeking behavior, which raises the hypothesis that an mGluR5-ERK1/2 pathway may regulate relapse to alcohol-seeking behavior. This interpretation is consistent with evidence showing that presentation of cues previously paired with ethanol injection can induce glutamate release (De Witte, 2004) and that activation of Group I metabotropic glutamate receptors (mGluR1 and 5) increases ERK1/2 phosphorylation in striatal neurons in vivo (Choe and Wang, 2001). Thus, we propose that exposure to alcohol-associated cues may upregulate ERK1/2 phosphorylation via increased glutamate activity at mGluR5 receptors in the nucleus accumbens shell and basolateral amygdala, which in turn mediates relapse-like behavior. However, increases in ERK1/2 phosphorylation are modulated by activity of a variety of cell surface proteins, including NMDA receptors (Valjent et al., 2000), which are coupled to mGluR5 and also regulate relapse-like behavior (Backstrom and Hyytia, 2006). For this reason, it remains to be determined whether mGluR5 blockade inhibited cue-induced reinstatement of alcohol-seeking behavior via ERK1/2 inhibition or whether the two effects of the mGluR5 antagonist were independent processes. Functional involvement of ERK1/2 activity in specific brain regions can be evaluated using a variety of approaches such as microinjection of a specific MEK/ERK1/2 inhibitor in specific brain regions, which has been shown to inhibit reinstatement of cocaine-seeking behavior (Lu et al., 2005).
The results of this study complement and extend a growing body of preclinical studies showing functional regulation of ethanol self-administration and relapse by metabotropic glutamate receptor activity. For instance, the mGluR5 antagonist MPEP reduces maintenance of operant alcohol self-administration as well as abstinence- and cue-induced relapse in rats (Backstrom et al., 2004; Schroeder et al., 2005) in the dose range of 2.5–10 mg/kg which has no effect on exploratory locomotor behavior in rodents (Henry et al., 2002; Tatarczynska et al., 2001). Other studies have shown that MPEP, or the more recently available mGluR5 antagonist MTEP, reduce alcohol self-administration in mice and rats under a variety of experimental conditions (Besheer et al., 2008; Cowen et al., 2005; Cowen et al., 2007; Hodge et al., 2006), which demonstrates interspecies generality and further supports specific involvement of mGluR5. In addition, agonism of presynaptic mGluR2/3 attenuates the ability of formerly drug-paired cues to reinstate responding (Zhao et al., 2006). Thus, it appears that inhibition of glutamate activity by blockade of postsynaptic mGluR5, or activation of presynaptic mGluR2/3, is sufficient to reduce alcohol self-administration and relapse-like behavior. It will be of interest to determine if reduced ERK1/2 activation is a common downstream mechanism by which mGluR5 antagonists or mGluR2/3 agonists prevent cue-induced reinstatement of alcohol-seeking behavior via inhibition of glutamate transmission
The results of this study are also consistent with numerous other studies implicating the basolateral amygdala and nucleus accumbens shell in relapse-like behavior. For example, evidence suggests that the basolateral nucleus of the amygdala regulates cue-induced reinstatement of cocaine- and food-seeking behavior (i.e., (Fuchs et al., 2006; Ghitza et al., 2003; Ledford et al., 2003; McLaughlin and Floresco, 2007; See et al., 2003). Functional inactivation of the BLA by excitotoxic lesions (Meil and See, 1997), microinjection of tetrodotoxin (Grimm and See, 2000) or lidocaine (Kantak et al., 2002) have all been shown to inhibit reinstatement of cocaine-seeking behavior following extinction (reviewed by (Everitt and Wolf, 2002). Other evidence indicates that activation of dopamine (Schmidt et al., 2006; Schmidt and Pierce, 2006) or Group II mGluRs (Bossert et al., 2006) in the nucleus accumbens shell regulates reinstatement of cocaine and heroin seeking-behavior. Overall, the results from these and numerous other studies suggest that the nucleus accumbens shell and basolateral amygdala are part of a mesocorticolimbic neural circuit that regulates cue-induced reinstatement of alcohol, drug, and food-seeking behavior after extinction.
Regulation of cue-induced reinstatement of alcohol-seeking behavior by an mGluR5 – ERK1/2 pathway in the basolateral amygdala and nucleus accumbens shell is consistent with the more general role of these proteins and brain regions in learning and memory. Considerable evidence indicates that the basolateral amygdala modulates memory consolidation in a number of tasks (Fuchs et al., 2006; Hatfield and McGaugh, 1999; Hsu et al., 2002; Lalumiere et al., 2004; Miranda et al., 2003; Schroeder and Packard, 2002, 2003, 2004) and growing evidence implicates ERK/MAPK and mGluR5 in these effects. For example, ERK1/2 is activated (i.e., phosphorylated) specifically in the lateral amygdala 60 min after Pavlovian fear conditioning in a manner that is dependent on tone-shock pairings, and site-specific infusion of the MEK/ERK inhibitor U0126 in the lateral amygdala impaired both long-term memory of Pavlovian fear conditioning and long-term potentiation in the lateral amygdala. This suggests that activation of the ERK/MAPK pathway is required for memory consolidation and synaptic plasticity in the amygdala (Schafe et al., 2000). Similarly, infusion of the mGluR5 antagonist MPEP in the amygdala blocks acquisition of contextual fear conditioning and long-term potentiation at thalamic input synapses to the lateral amygdala (Rodrigues et al., 2002). Moreover, the BLA has a direct glutamatergic projection to the nucleus accumbens (Kelley et al., 1982; Robinson and Beart, 1988) and evidence indicates that the basolateral amygdala and nucleus accumbens shell (but not the core) interactively modulate memory consolidation (LaLumiere et al., 2005). Thus, it is plausible that increased ERK1/2 phosphorylation in the basolateral amygdala and nucleus accumbens shell in the present study may reflect activation of a memory circuit that processes information about stimuli that are paired with alcohol during voluntary self-administration. Together, these results underscore the many conceptual and mechanistic overlaps between the neurobiology of addiction and memory (Kelley, 2004).
Although the present data raise the possibility that that the mGluR5 antagonist MPEP blocked cue-induced reinstatement of alcohol-seeking by inhibiting the associated increase in ERK1/2 phosphorylation, a number of potential alternative explanations and limitations to this study should be discussed. First, an alternative to the interpretation that MPEP specifically reduced cue-induced reinstatement is that injection of the mGluR5 antagonist may have reduced general locomotor activity. However, evidence indicates that the highest dose of MPEP (10 mg/kg) tested in the present study has no effect on exploratory locomotor behavior in P-rats with a history of alcohol self-administration (Besheer et al., 2008). Second, MPEP may have reduced cue-induced reinstatement by producing a negative affective state in the subjects. This possibility also appears unlikely as previous research indicates that MPEP does not produce a conditioned place preference or conditioned place aversion (McGeehan and Olive, 2003; Popik and Wrobel, 2002). Moreover, MPEP alone does not produce a subjective (i.e., discriminative) stimulus effect that resembles alcohol (Besheer and Hodge, 2005), which suggests that the compound did not act as an alcohol substitute. Third, a limitation of the present study is that these results show an association between the behavioral effects of MPEP and the changes in ERK1/2 activation but do not demonstrate functional involvement of ERK1/2 in reinstatement. Studies that directly manipulate ERK1/2 activation either systemically or in specific brain regions are required to show functional involvement. Fourth, it will be important in future studies to dissociate the effects of alcohol-seeking from cue presentation on ERK1/2 activation to rule out any potential interactions between lever press behavior and subsequent changes in ERK1/2 phosphorylation. This can be addressed by including a cue-only control or conducting studies examining effects of contextual cues, which may alter ERK1/2 activation. Finally, one of the main goals of this study was to examine cue-induced changes in ERK1/2 activity after extinction of alcohol-seeking behavior; however, this approach did not address potential effects of extinction on ERK1/2 activity, which might be expected since extinction is an active learning process (Schroeder and Packard, 2003).
Similar to ERK1/2, extracellular-signal-regulated kinase 5 (ERK5) is a member of the multigene MAP kinase family that is activated (i.e., phosphorylated) by MEK5. Although ERK1/2 is activated by the separate MEK1/2 pathway, these two MAP kinases share a number of structural and functional properties that suggest common activities. For example, both ERK1/2 and ERK5 have a Thr–Glu–Tyr activation motif and show 50% homology of the N-terminal catalytic domain (Nishimoto and Nishida, 2006), are activated by platelet-derived growth factor (Abe et al., 1996), and are inhibited by the commonly used MEK1/2 inhibitors, PD98059, U0126, and PD184352 (Kamakura et al., 1999; Mody et al., 2001), which are commonly thought to specifically inhibit ERK1/2 activation. For these reasons, we also examined immunoreactivity of the phosphorylated (i.e., active) form of ERK5 (p-ERK5) in the nucleus accumbens and amygdala as a measure of ERK1/2 specificity. P-ERK5 IR was detected at high levels in all subnuclei of the nucleus accumbens and amygdala. However, no changes were observed in p-ERK5 IR following cue-induced reinstatement of alcohol-seeking behavior or administration of MPEP. These data indicate that the observed effects on ERK1/2 phosphorylation were not associated with nonspecific activation of MAPK pathways. It remains to be determined if phosphorylation of other MAPKs, such as JNK or p38, is altered during relapse-like behavior.
In conclusion, the MAP kinases have been associated with many of the negative health effects of alcohol including liver disease, pancreatitis, cancer risk, neurotoxicity, and cardiovascular disease (Aroor and Shukla, 2004). Results of this study show for the first time that ERK1/2 is activated in specific sub-nuclei of the amygdala-ventral striatal pathway by response-contingent presentation of alcohol-associated stimuli. Concomitant blockade of the ERK1/2 activation and relapse-like behavior by the mGluR5 antagonist MPEP suggests that cue-induced reinstatement of alcohol-seeking may be functionally regulated by an mGluR5 – ERK1/2 pathway. Overall, these results provide further support for the potential utility of mGluR5 antagonists in the treatment of problems associated with alcoholism such as relapse, and provide a novel molecular mechanism by which these compounds may change brain and behavioral function.
Acknowledgements
This work was supported by Grants AA11605 and AA014983 to CWH from the National Institute on Alcohol Abuse and Alcoholism and by funds from the Alcoholic Beverage Medical Research Foundation to JPS.
Footnotes
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  • Abe J, Kusuhara M, Ulevitch RJ, Berk BC, Lee JD. Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase. J Biol Chem. 1996;271:16586–16590. [PubMed]
  • Anderson NG, Maller JL, Tonks NK, Sturgill TW. Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature. 1990;343:651–653. [PubMed]
  • Anton RF, Kranzler HR, Meyer RE. Neurobehavioral aspects of the pharmacotherapy of alcohol dependence. Clin Neurosci. 1995;3:145–154. [PubMed]
  • Aroor AR, Shukla SD. MAP kinase signaling in diverse effects of ethanol. Life Sci. 2004;74:2339–2364. [PubMed]
  • Bachtell RK, Tsivkovskaia NO, Ryabinin AE. Alcohol-induced c-Fos expression in the Edinger-Westphal nucleus: pharmacological and signal transduction mechanisms. J Pharmacol Exp Ther. 2002;302:516–524. [PubMed]
  • Backstrom P, Bachteler D, Koch S, Hyytia P, Spanagel R. mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behavior. Neuropsychopharmacology. 2004;29:921–928. [PubMed]
  • Backstrom P, Hyytia P. Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology. 2006;31:778–786. [PubMed]
  • Besheer J, Cox AA, Hodge CW. Coregulation of ethanol discrimination by the nucleus accumbens and amygdala. Alcohol Clin Exp Res. 2003;27:450–456. [PubMed]
  • Besheer J, Faccidomo S, Grondin JJ, Hodge CW. Regulation of motivation to self-administer ethanol by mGluR5 in alcohol-preferring (P) rats. Alcohol Clin Exp Res. 2008;32:209–221. [PMC free article] [PubMed]
  • Besheer J, Hodge CW. Pharmacological and anatomical evidence for an interaction between mGluR5- and GABA(A) alpha1-containing receptors in the discriminative stimulus effects of ethanol. Neuropsychopharmacology. 2005;30:747–757. [PMC free article] [PubMed]
  • Besheer J, Stevenson RA, Hodge CW. mGlu5 receptors are involved in the discriminative stimulus effects of self-administered ethanol in rats. Eur J Pharmacol. 2006;551:71–75. [PMC free article] [PubMed]
  • Bossert JM, Gray SM, Lu L, Shaham Y. Activation of group II metabotropic glutamate receptors in the nucleus accumbens shell attenuates context-induced relapse to heroin seeking. Neuropsychopharmacology. 2006;31:2197–2209. [PMC free article] [PubMed]
  • Breese GR, Overstreet DH, Knapp DJ. Conceptual framework for the etiology of alcoholism: a "kindling"/stress hypothesis. Psychopharmacology (Berl) 2005;178:367–380. [PMC free article] [PubMed]
  • Chandler LJ, Sutton G. Acute ethanol inhibits extracellular signal-regulated kinase, protein kinase B, and adenosine 3':5'-cyclic monophosphate response element binding protein activity in an age- and brain region-specific manner. Alcohol Clin Exp Res. 2005;29:672–682. [PubMed]
  • Choe ES, Wang JQ. Group I metabotropic glutamate receptors control phosphorylation of CREB, Elk-1 and ERK via a CaMKII-dependent pathway in rat striatum. Neurosci Lett. 2001;313:129–132. [PubMed]
  • Cicero T, editor. A critique of animal analogs of alcoholism. New York: Plenum Press; 1979.
  • Cobb MH. MAP kinase pathways. Prog Biophys Mol Biol. 1999;71:479–500. [PubMed]
  • Cowen MS, Djouma E, Lawrence AJ. The metabotropic glutamate 5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine reduces ethanol self-administration in multiple strains of alcohol-preferring rats and regulates olfactory glutamatergic systems. J Pharmacol Exp Ther. 2005;315:590–600. [PubMed]
  • Cowen MS, Krstew E, Lawrence AJ. Assessing appetitive and consummatory phases of ethanol self-administration in C57BL/6J mice under operant conditions: regulation by mGlu5 receptor antagonism. Psychopharmacology (Berl) 2007;190:21–29. [PubMed]
  • Crews FT, Morrow AL, Criswell H, Breese G. Effects of ethanol on ion channels. Int Rev Neurobiol. 1996;39:283–367. [PubMed]
  • Davis MI, Szarowski D, Turner JN, Morrisett RA, Shain W. In vivo activation and in situ BDNF-stimulated nuclear translocation of mitogen-activated/extracellular signal-regulated protein kinase is inhibited by ethanol in the developing rat hippocampus. Neurosci Lett. 1999;272:95–98. [PubMed]
  • Dayas CV, Liu X, Simms JA, Weiss F. Distinct patterns of neural activation associated with ethanol seeking: effects of naltrexone. Biol Psychiatry. 2007;61:979–989. [PMC free article] [PubMed]
  • De Witte P. Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol. Addict Behav. 2004;29:1325–1339. [PubMed]
  • Everitt BJ, Parkinson JA, Olmstead MC, Arroyo M, Robledo P, Robbins TW. Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann N Y Acad Sci. 1999;877:412–438. [PubMed]
  • Everitt BJ, Wolf ME. Psychomotor stimulant addiction: a neural systems perspective. J Neurosci. 2002;22:3312–3320. [PubMed]
  • Fadda F, Rossetti ZL. Chronic ethanol consumption: from neuroadaptation to neurodegeneration. Prog Neurobiol. 1998;56:385–431. [PubMed]
  • Fuchs RA, Feltenstein MW, See RE. The role of the basolateral amygdala in stimulus-reward memory and extinction memory consolidation and in subsequent conditioned cued reinstatement of cocaine seeking. Eur J Neurosci. 2006;23:2809–2813. [PubMed]
  • Ghitza UE, Fabbricatore AT, Prokopenko V, Pawlak AP, West MO. Persistent cue-evoked activity of accumbens neurons after prolonged abstinence from self-administered cocaine. J Neurosci. 2003;23:7239–7245. [PubMed]
  • Girault JA, Valjent E, Caboche J, Herve D. ERK2: a logical AND gate critical for drug-induced plasticity. Curr Opin Pharmacol. 2007;7:77–85. [PubMed]
  • Grewal SS, York RD, Stork PJ. Extracellular-signal-regulated kinase signalling in neurons. Curr Opin Neurobiol. 1999;9:544–553. [PubMed]
  • Hatfield T, McGaugh JL. Norepinephrine infused into the basolateral amygdala posttraining enhances retention in a spatial water maze task. Neurobiol Learn Mem. 1999;71:232–239. [PubMed]
  • Heinz A, Schafer M, Higley JD, Krystal JH, Goldman D. Neurobiological correlates of the disposition and maintenance of alcoholism. Pharmacopsychiatry. 2003;36 Suppl 3:S255–S258. [PubMed]
  • Henry SA, Lehmann-Masten V, Gasparini F, Geyer MA, Markou A. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology. 2002;43:1199–1209. [PubMed]
  • Hodge CW, Chappelle AM, Samson HH. GABAergic transmission in the nucleus accumbens is involved in the termination of ethanol self-administration in rats. Alcohol Clin Exp Res. 1995;19:1486–1493. [PubMed]
  • Hodge CW, Cox AA. The discriminative stimulus effects of ethanol are mediated by NMDA and GABA(A) receptors in specific limbic brain regions. Psychopharmacology (Berl) 1998;139:95–107. [PubMed]
  • Hodge CW, Miles MF, Sharko AC, Stevenson RA, Hillmann JR, Lepoutre V, Besheer J, Schroeder JP. The mGluR5 antagonist MPEP selectively inhibits the onset and maintenance of ethanol self-administration in C57BL/6J mice. Psychopharmacology (Berl) 2006;183:429–438. [PMC free article] [PubMed]
  • Hodge CW, Samson HH, Lewis RS, Erickson HL. Specific decreases in ethanol- but not water-reinforced responding produced by the 5-HT3 antagonist ICS 205–930. Alcohol. 1993;10:191–196. [PubMed]
  • Hsu EH, Schroeder JP, Packard MG. The amygdala mediates memory consolidation for an amphetamine conditioned place preference. Behav Brain Res. 2002;129:93–100. [PubMed]
  • Kalluri HS, Ticku MK. Ethanol-mediated inhibition of mitogen-activated protein kinase phosphorylation in mouse brain. Eur J Pharmacol. 2002a;439:53–58. [PubMed]
  • Kalluri HS, Ticku MK. Role of GABA(A) receptors in the ethanol-mediated inhibition of extracellular signal-regulated kinase. Eur J Pharmacol. 2002b;451:51–54. [PubMed]
  • Kamakura S, Moriguchi T, Nishida E. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem. 1999;274:26563–26571. [PubMed]
  • Kampov-Polevoy AB, Matthews DB, Gause L, Morrow AL, Overstreet DH. P rats develop physical dependence on alcohol via voluntary drinking: changes in seizure thresholds, anxiety, and patterns of alcohol drinking. Alcohol Clin Exp Res. 2000;24:278–284. [PubMed]
  • Kelley AE. Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron. 2004;44:161–179. [PubMed]
  • Kelley AE, Domesick VB, Nauta WJ. The amygdalostriatal projection in the rat--an anatomical study by anterograde and retrograde tracing methods. Neuroscience. 1982;7:615–630. [PubMed]
  • LaLumiere RT, Nawar EM, McGaugh JL. Modulation of memory consolidation by the basolateral amygdala or nucleus accumbens shell requires concurrent dopamine receptor activation in both brain regions. Learn Mem. 2005;12:296–301. [PubMed]
  • Lalumiere RT, Nguyen LT, McGaugh JL. Post-training intrabasolateral amygdale infusions of dopamine modulate consolidation of inhibitory avoidance memory: involvement of noradrenergic and cholinergic systems. Eur J Neurosci. 2004;20:2804–2810. [PubMed]
  • Ledford CC, Fuchs RA, See RE. Potentiated reinstatement of cocaine-seeking behavior following D-amphetamine infusion into the basolateral amygdala. Neuropsychopharmacology. 2003;28:1721–1729. [PubMed]
  • Lester D, Freed EX. Criteria for an animal model of alcoholism. Pharmacol Biochem Behav. 1973;1:103–107. [PubMed]
  • Li T, Lumeng L, McBride W, Murphy J. Rodent lines selected for factors affecting alcohol consumption. Alcohol Alcohol Suppl. 1987;1:91–96. [PubMed]
  • Li TK, Lumeng L, McBride WJ, Waller MB. Progress toward a voluntary oral consumption model of alcoholism. Drug Alcohol Depend. 1979;4:45–60. [PubMed]
  • Lu L, Hope BT, Dempsey J, Liu SY, Bossert JM, Shaham Y. Central amygdale ERK signaling pathway is critical to incubation of cocaine craving. Nat Neurosci. 2005;8:212–219. [PubMed]
  • Mann K. Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs. 2004;18:485–504. [PubMed]
  • McGeehan AJ, Olive MF. The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse. Synapse. 2003;47:240–242. [PubMed]
  • McLaughlin RJ, Floresco SB. The role of different subregions of the basolateral amygdala in cue-induced reinstatement and extinction of food-seeking behavior. Neuroscience. 2007;146:1484–1494. [PubMed]
  • Minami K, Gereau RWt, Minami M, Heinemann SF, Harris RA. Effects of ethanol and anesthetics on type 1 and 5 metabotropic glutamate receptors expressed in Xenopus laevis oocytes. Mol Pharmacol. 1998;53:148–156. [PubMed]
  • Miranda MI, LaLumiere RT, Buen TV, Bermudez-Rattoni F, McGaugh JL. Blockade of noradrenergic receptors in the basolateral amygdala impairs taste memory. Eur J Neurosci. 2003;18:2605–2610. [PubMed]
  • Mody N, Leitch J, Armstrong C, Dixon J, Cohen P. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett. 2001;502:21–24. [PubMed]
  • Murphy J, Stewart R, Bell R, Badia-Elder N, Carr L, McBride W, Lumeng L, Li T. Phenotypic and genotypic characterization of the Indiana University rat lines selectively bred for high and low alcohol preference. Behavioral Genetics. 2002;32:363–388. [PubMed]
  • Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science. 1997;278:58–63. [PubMed]
  • Nishimoto S, Nishida E. MAPK signalling: ERK5 versus ERK1/2. EMBO Rep. 2006;7:782–786. [PubMed]
  • Pandey SC, Roy A, Zhang H. The decreased phosphorylation of cyclic adenosine monophosphate (cAMP) response element binding (CREB) protein in the central amygdala acts as a molecular substrate for anxiety related to ethanol withdrawal in rats. Alcohol Clin Exp Res. 2003;27:396–409. [PubMed]
  • Pandey SC, Zhang H, Ugale R, Prakash A, Xu T, Misra K. Effector immediate-early gene arc in the amygdala plays a critical role in alcoholism. J Neurosci. 2008;28:2589–2600. [PubMed]
  • Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22:153–183. [PubMed]
  • Popik P, Wrobel M. Morphine conditioned reward is inhibited by MPEP, the mGluR5 antagonist. Neuropharmacology. 2002;43:1210–1217. [PubMed]
  • Qi M, Elion EA. MAP kinase pathways. J Cell Sci. 2005;118:3569–3572. [PubMed]
  • Radwanska K, Wrobel E, Korkosz A, Rogowski A, Kostowski W, Bienkowski P, Kaczmarek L. Alcohol Relapse Induced by Discrete Cues Activates Components of AP-1 Transcription Factor and ERK Pathway in the Rat Basolateral and Central Amygdala. Neuropsychopharmacology. 2008;33:1835–1846. [PubMed]
  • Robinson TG, Beart PM. Excitant amino acid projections from rat amygdala and thalamus to nucleus accumbens. Brain Res Bull. 1988;20:467–471. [PubMed]
  • Rodrigues SM, Bauer EP, Farb CR, Schafe GE, LeDoux JE. The group I metabotropic glutamate receptor mGluR5 is required for fear memory formation and long-term potentiation in the lateral amygdala. J Neurosci. 2002;22:5219–5229. [PubMed]
  • Ron D, Jurd R. The "ups and downs" of signaling cascades in addiction. Sci STKE 2005. 2005:re14. [PubMed]
  • Samson HH. Initiation of ethanol reinforcement using a sucrose-substitution procedure in food- and water-sated rats. Alcohol Clin Exp Res. 1986;10:436–442. [PubMed]
  • Sanna PP, Simpson C, Lutjens R, Koob G. ERK regulation in chronic ethanol exposure and withdrawal. Brain Res. 2002;948:186–191. [PubMed]
  • Schafe GE, Atkins CM, Swank MW, Bauer EP, Sweatt JD, LeDoux JE. Activation of ERK/MAP kinase in the amygdala is required for memory consolidation of pavlovian fear conditioning. J Neurosci. 2000;20:8177–8187. [PubMed]
  • Schmidt HD, Anderson SM, Pierce RC. Stimulation of D1-like or D2 dopamine receptors in the shell, but not the core, of the nucleus accumbens reinstates cocaine-seeking behaviour in the rat. Eur J Neurosci. 2006;23:219–228. [PubMed]
  • Schmidt HD, Pierce RC. Cooperative activation of D1-like and D2-like dopamine receptors in the nucleus accumbens shell is required for the reinstatement of cocaine-seeking behavior in the rat. Neuroscience. 2006;142:451–461. [PubMed]
  • Schneider F, Habel U, Wagner M, Franke P, Salloum JB, Shah NJ, Toni I, Sulzbach C, Honig K, Maier W, Gaebel W, Zilles K. Subcortical correlates of craving in recently abstinent alcoholic patients. Am J Psychiatry. 2001;158:1075–1083. [PubMed]
  • Schroeder JP, Olive F, Koenig H, Hodge CW. Intra-amygdala infusion of the NPY Y1 receptor antagonist BIBP 3226 attenuates operant ethanol self-administration. Alcohol Clin Exp Res. 2003;27:1884–1891. [PubMed]
  • Schroeder JP, Overstreet DH, Hodge CW. The mGluR5 antagonist MPEP decreases operant ethanol self-administration during maintenance and after repeated alcohol deprivations in alcohol-preferring (P) rats. Psychopharmacology (Berl) 2005;179:262–270. [PubMed]
  • Schroeder JP, Packard MG. Posttraining intra-basolateral amygdala scopolamine impairs food- and amphetamine-induced conditioned place preferences. Behav Neurosci. 2002;116:922–927. [PubMed]
  • Schroeder JP, Packard MG. Systemic or intra-amygdala injections of glucose facilitate memory consolidation for extinction of drug-induced conditioned reward. Eur J Neurosci. 2003;17:1482–1488. [PubMed]
  • Schroeder JP, Packard MG. Facilitation of memory for extinction of drug-induced conditioned reward: role of amygdala and acetylcholine. Learn Mem. 2004;11:641–647. [PubMed]
  • See RE, McLaughlin J, Fuchs RA. Muscarinic receptor antagonism in the basolateral amygdala blocks acquisition of cocaine-stimulus association in a model of relapse to cocaine-seeking behavior in rats. Neuroscience. 2003;117:477–483. [PubMed]
  • Sweatt JD. Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol. 2004;14:311–317. [PubMed]
  • Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R, Pilc A. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol. 2001;132:1423–1430. [PubMed]
  • Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci. 2004;5:173–183. [PubMed]
  • Treisman R. Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol. 1996;8:205–215. [PubMed]
  • Tsuji R, Guizzetti M, Costa LG. In vivo ethanol decreases phosphorylated MAPK and p70S6 kinase in the developing rat brain. Neuroreport. 2003;14:1395–1399. [PubMed]
  • Valjent E, Corvol JC, Pages C, Besson MJ, Maldonado R, Caboche J. Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties. J Neurosci. 2000;20:8701–8709. [PubMed]
  • Valjent E, Corvol JC, Trzaskos JM, Girault JA, Herve D. Role of the ERK pathway in psychostimulant-induced locomotor sensitization. BMC Neurosci. 2006;7:20. [PMC free article] [PubMed]
  • Yang L, Mao L, Tang Q, Samdani S, Liu Z, Wang JQ. A novel Ca2+independent signaling pathway to extracellular signal-regulated protein kinase by coactivation of NMDA receptors and metabotropic glutamate receptor 5 in neurons. J Neurosci. 2004;24:10846–10857. [PubMed]
  • Zhao Y, Dayas CV, Aujla H, Baptista MA, Martin-Fardon R, Weiss F. Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala. J Neurosci. 2006;26:9967–9974. [PubMed]